Recreational drugs, 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxyamphetamine (MDA) and diphenylprolinol, inhibit neurite outgrowth in PC12 cells

Journal of Toxicological Sciences

Volumn 35, Issue 3, 2010, Pages 375-381

  Kaizaki, Asuka ^a   Tanaka, Sachiko ^a   Tsujikawa, Kenji ^b   Numazawa, Satoshi ^a   Yoshida, Takemi ^a  

^a SHOWA UNIVERSITY   (Japan)

^b NATIONAL RESEARCH INSTITUTE OF POLICE SCIENCE   (Japan)

Author keywords

Diphenylprolinol; MDA; MDMA; Neurite outgrowth; PC12; Recreational drug

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DIPHENYLPROLINOL; NERVE GROWTH FACTOR; PIPRADOL; RECREATIONAL DRUG; UNCLASSIFIED DRUG; 3,4 METHYLENEDIOXYAMPHETAMINE; PROLINE; STREET DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; CELL DEATH; CELL STRAIN; CELL VIABILITY; CHEMICAL STRUCTURE; CYTOTOXICITY; DRUG ABUSE; DRUG EFFECT; DRUG SYNTHESIS; IC 50; NERVE FIBER GROWTH; NEUROTOXICITY; NONHUMAN; RAT; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICAL PHENOMENA; DRUG EFFECTS; NEURITE; PC12 CELL LINE; PHYSIOLOGY; TOXICITY;

3,4-METHYLENEDIOXYAMPHETAMINE; ANIMALS; DEPRESSION, CHEMICAL; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE GROWTH FACTOR; NEURITES; PC12 CELLS; PROLINE; RATS; STREET DRUGS;

EID: 77953295830     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.35.375     Document Type: Article

References (26)

1. Altun-Gultekin, Z.F., Chandriani, S., Bougeret, C., Ishizaki, T., Narumiya, S., de Graaf, P., Van Bergen en Henegouwen, P., Hanafusa, H., Wagner, J.A. and Birge, R.B. (1998): Activation of Rho-dependent cell spreading and focal adhesion biogenesis by the v-Crk adaptor protein. Mol. Cell Biol., 18, 3044-3058.
2. Battaglia, G., Yeh, S.Y., O'Hearn, E., Molliver, M.E., Kuhar, M.J. and De Souza, E.B. (1987): 3,4-Methylenedioxymethamphetamine and 3,4- methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H] paroxetine-labeled serotonin uptake sites. J. Pharmacol. Exp. Ther., 242, 911-916.
3. Colado, M.I., Murray, T.K. and Green, A.R. (1993): 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br. J. Pharmacol., 108, 583-589.
4. de la Torre, R., Farré, M., Roset, P.N., Pizarro, N., Abanades, S., Segura, M., Segura, J. and Camí, J. (2004): Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther. Drug Monit., 26, 137-144.
5. Downing, J. (1986): The psychological and physiological effects of MDMA on normal volunteers. J. Psychoactive Drugs, 18, 335-340.
6. Duan, W.G., Shang, J., Jiang, Z.Z., Yao, J.C., Yun, Y., Yan, M., Shu, B., Lin, Q., Yu, Z.P. and Zhang, L.Y. (2009): Rho kinase inhibitor Y-27632 down-regulates norepinephrine synthesis and release in PC12 cells. Basic Clin. Pharmacol. Toxicol., 104, 434-440.
7. Freudenmann, R.W., Oxler, F. and Bernschneider-Reif, S. (2006): The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction., 101, 1241-1245. (Pubitemid 44202058)
8. Gelvin, E.P., McGavack, T.H. and Kenigsberg, S. (1955): Alpha-(2-piperidyl) benzhydrol hydrochloride (pipradrol) as an adjunct in the dietary management of obesity. N Y State J. Med., 55, 2336-2338.
9. Greene, L.A. and Tischler, A.S. (1976): Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. PNAS, 73, 2424-2428.
10. Gudelsky, G.A. and Nash, J.F. (1996): Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J. Neurochem., 66, 243-249. (Pubitemid 26010787)
11. Lidder, S., Dargan, P., Sexton, M., Button, J., Ramsey, J., Holt, D. and Wood, D. (2008): Cardiovascular toxicity associated with recreational use of diphenylprolinol (diphenyl-2-pyrrolidinemethanol [D2PM]). J. Med. Toxicol., 4, 167-169.
12. Liechti, M.E., Baumann, C., Gamma, A. and Vollenweider, F.X. (2000): Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology, 22, 513-521. (Pubitemid 30145619)
13. Makino, Y., Tanaka, S., Kurobane, S., Nakauchi, M.,Terasaki, T. and Ohta, S. (2003): Profiling of Illegal Amphetamine-type Stimulant Tablets in Japan. J. Health Sci., 49, 129-137. (Pubitemid 41301480)
14. Marshall, C.J. (1995): Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell, 80, 179-185.
15. Mérot, Y., Ferrière, F., Gailhouste, L., Huet, G., Percevault, F., Saligaut, C. and Flouriot, G. (2009): Different outcomes of unliganded and liganded estrogen receptor-alpha on neurite outgrowth in PC12 cells. Endocrinology, 150, 200-211.
16. O'Donnell, M., Nassar, N., Leonard, H., Hagan, R., Mathews, R., Patterson, Y. and Stanley, F. (2009): Increasing prevalence of neonatal withdrawal syndrome: population study of maternal factors and child protection involvement. Pediatrics, 123, 614-621.
17. O'Shea, E., Granados, R., Esteban, B., Colado, M.I. and Green, A.R. (1998): The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology, 37, 919-926.
18. Parrott, A.C. (2001): Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum. Psychopharmacol., 16, 557-577.
19. Parrott, A.C. (2002): Recreational Ecstasy/MDMA, the seroto nin syndrome, and serotonergic neurotoxicity. Pharmacol. Biochem. Behav., 71, 837-844.
20. Parrott, A.C. (2005): Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. J. Psychopharmacol., 19, 71-83.
21. Portoghese, P.S., Pazdernik, T.L., Kuhn, W.L., Hite, G. and Shafi'ee, A. (1968): Stereochemical studies on medicinal agents. V. Synthesis, configuration, and pharmacological activity of pipradrol enantiomers. J. Med. Chem., 11, 12-15.
22. Rothman, R.B. and Baumann, M.H. (2002): Therapeutic and adverse actions of serotonin nerve transporter substrates. Pharmacol. Ther., 95, 73-88.
23. Ricaurte, G., Bryan, G., Strauss, L., Seiden, L. and Schuster, C. (1985): Hallucinogenic amphetamine selectively destroys brain serotonin terminals. Science, 229, 986-988. (Pubitemid 16248493)
24. Schmidt, C.J. and Taylor, V.L. (1987): Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymetamphetamine. Biochem. Pharmacol., 36, 4095-4102.
25. Shulgin, A. and Shulgin, A. (1991): PiHKAL : A Chemical Love Story. (Dan, J., ed.), pp.714-719, pp.733-739, Transform Press, Berkeley.
26. Wagner, C.L., Katikaneni, L.D., Cox, T.H. and Ryan, R.M. (1998): The impact of prenatal drug exposure on the neonate. Obstet. Gynecol. Clin. North Am., 25, 169-194.